Taspoglutide
- Generic Name
- Taspoglutide
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C152H232N40O45
- CAS Number
- 275371-94-3
- Unique Ingredient Identifier
- 2PHK27IP3B
- Background
Taspoglutide is a pharmaceutical drug, a glucagon-like peptide-1 agonist (GLP-1 agonist), under investigation for treatment of type 2 diabetes being codeveloped by Ipsen and Roche. In September 2010 Roche halted Phase III clinical trials due to incidences of serious hypersensitivity reactions and gastrointestinal side effects. As of May 2013 no new trials had been registered.
- Associated Conditions
- -
- Associated Therapies
- -
A Study of Taspoglutide Versus Exenatide for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, Thiazolidinedione or a Combination of Both.
- First Posted Date
- 2008-07-17
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1189
- Registration Number
- NCT00717457
A Study of a GLP-1 Analogue in Patients With Type 2 Diabetes Treated With Metformin.
- First Posted Date
- 2007-01-18
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 306
- Registration Number
- NCT00423501
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath